Stock DSGN DESIGN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
3.8 USD -1.30% Intraday chart for Design Therapeutics, Inc. -6.63% +43.40%
May. 08 Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
GL
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
GL
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
GL
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
GL
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
GL
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
PR
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
GL
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
GL
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
GL
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
AQ
DESIGN THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
GL
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
GL
DESIGN THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DSGN Stock
  4. News Design Therapeutics, Inc.
  5. Press Releases